Magnetic resonance spectroscopic evidence for presupplementary motor area neuronal dysfunction in Parkinson's disease

Movement Disorders

Volumn 22, Issue 3, 2007, Pages 382-386

  Camicioli, Richard M ^a,b   Hanstock, Christopher C ^a   Bouchard, Thomas P ^a   Gee, Myrlene ^a   Fisher, Nancy J ^a   Martin, W R Wayne ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b GLENROSE REHABILITATION HOSPITAL   (Canada)

Author keywords

Hoehn and Yahr rating; Magnetic resonance spectroscopy; Motor signs; Parkinson's disease; Unified Parkinson's disease rating scale

Indexed keywords

BIOLOGICAL MARKER; BROMOCRIPTINE; DOPAMINE; LEVODOPA; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE;

AGED; ARTICLE; CINGULATE GYRUS; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; DISEASE DURATION; FEMALE; GERIATRIC DEPRESSION SCALE; GRAY MATTER; HUMAN; MALE; MINI MENTAL STATE EXAMINATION; MOTOR DYSFUNCTION; MOTOR NEURON DISEASE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARKINSON DISEASE; PRIORITY JOURNAL; RADIODIAGNOSIS; UNIFIED PARKINSON DISEASE RATING SCALE; WHITE MATTER;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MOTOR CORTEX; PARKINSON DISEASE;

EID: 34147107506     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21288     Document Type: Article

References (36)

1. Ma SY, Roytta M, Rinne JO, Collan Y, Rinne UK. Correlation between neuromorphometry in the substantia nigra and clinical features in Parkinson's disease using disector counts. J Neurol Sci 1997;151:83-87.
2. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Ann Neurol 1996;39:37-45.
3. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004;318:121-134.
4. Diederich NJ, Moore CG, Leurgans SE, Chmura TA, Goetz CG. Parkinson disease with old-age onset: a comparative study with subjects with middle-age onset. Arch Neurol 2003;60:529-533.
5. Jenkins IH, Fernandez W, Playford ED, et al. Impaired activation of the supplementary motor area in Parkinson's disease is reversed when akinesia is treated with apomorphine. Ann Neurol 1992;32: 749-757.
6. Rascol O, Sabatini U, Chollet F, et al. Normal activation of the supplementary motor area in patients with Parkinson's disease undergoing long-term treatment with levodopa. J Neurol Neurosurg Psychiatry 1994;57:567-571.
7. Haslinger B, Erhard P, Kampfe N, et al. Event-related functional magnetic resonance imaging in Parkinson's disease before and after levodopa. Brain 2001;124:558-570.
8. Eckert T, Peschel T, Heinze HJ, Rotte M. Increased pre-SMA activation in early PD patients during simple self-initiated hand movements. J Neurol 2006;253:199-207.
9. MacDonald V, Halliday GM. Selective loss of pyramidal neurons in the pre-supplementary motor cortex in Parkinson's disease. Mov Disord 2002;17:1166-1173.
10. Adalsteinsson E, Sullivan EV, Kleinhans N, Spielman DM, Pfefferbaum A. Longitudinal decline of the neuronal marker N-acetyl aspartate in Alzheimer's disease. Lancet 2000;355:1696-1697.
11. Kovari E, Gold G, Herrmann FR, et al. Lewy body densities in the entorhinal and anterior cingulate cortex predict cognitive deficits in Parkinson's disease. Acta Neuropathol (Berl) 2003;106:83-88.
12. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-752.
13. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
14. Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a frontal assessment battery at bedside. Neurology 2000;55:1621-1626.
15. Yesavage JA. Geriatric depression scale. Psychopharmacol Bull 1988;24:709-711.
16. Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A. Pathological verification of ischemic score in differentiation of dementias. Ann Neurol 1980;7:486-488.
17. Gancher ST. Scales for the assessment of movement disorders. In: Herndon RM, editor. Handbook of neurologic rating scales. New York: Demos Vermande; 1997. p 81-106.
18. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442.
19. Camicioli RM, Korzan JR, Foster SL, et al. Posterior cingulate metabolic changes occur in Parkinson's disease patients without dementia. Neurosci Lett 2004;354:177-180.
20. Talairach J, Tournoux P. Co-planar stereotaxic atlas of the human brain. New York: Thieme; 1988.
21. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 1993;30: 672-679.
22. Clarke CE, Lowry M. Systematic review of proton magnetic resonance spectroscopy of the striatum in parkinsonian syndromes. Eur J Neurol 2001;8:573-577.
23. Watanabe H, Fukatsu H, Katsuno M, et al. Multiple regional 1H-MR spectroscopy in multiple system atrophy: NAA/Cr reduction in pontine base as a valuable diagnostic marker. J Neurol Neurosurg Psychiatry 2004;75:103-109.
24. Axelson D, Bakken U, Susann Gribbestad I, Ehrnholm B, Nilsen G, Aasly J. Applications of neural network analyses to in vivo 1H magnetic resonance spectroscopy of Parkinson disease patients. J Magn Reson Imaging 2002;16:13-20.
25. Taylor-Robinson SD, Turjanski N, Bhattacharya S, et al. A proton magnetic resonance spectroscopy study of the striatum and cerebral cortex in Parkinson's disease. Metab Brain Dis 1999;14:45-55.
26. Hu MT, Taylor-Robinson SD, Chaudhuri KR, et al. Evidence for cortical dysfunction in clinically non-demented patients with Parkinson's disease: a proton MR spectroscopy study. J Neurol Neurosurg Psychiatry 1999;67:20-26.
27. Summerfield C, Gomez-Anson B, Tolosa E, et al. Dementia in Parkinson disease: a proton magnetic resonance spectroscopy study. Arch Neurol 2002;59:1415-1420.
28. Tedeschi G, Litvan I, Bonavita S, et al. Proton magnetic resonance spectroscopic imaging in progressive supranuclear palsy, Parkinson's disease and corticobasal degeneration. Brain 1997;120(Pt. 9):1541-1552.
29. Lucetti C, Del Dotto P, Gambaccini G, et al. Proton magnetic resonance spectroscopy (1H-MRS) of motor cortex and basal ganglia in de novo Parkinson's disease patients. Neurol Sci 2001;22: 69-70.
30. Firbank MJ, Harrison RM, O'Brien JT. A comprehensive review of proton magnetic resonance spectroscopy studies in dementia and Parkinson's disease. Dement Geriatr Cogn Disord 2002;14:64-76.
31. Lehericy S, Ducros M, Krainik A, et al. 3-D diffusion tensor axonal tracking shows distinct SMA and pre-SMA projections to the human striatum. Cereb Cortex 2004;14:1302-1309.
32. Sabatini U, Boulanouar K, Fabre N, et al. Cortical motor reorganization in akinetic patients with Parkinson's disease: a functional MRI study. Brain 2000;123(Pt. 2):394-403.
33. Alves G, Wentzel-Larsen T, Aarsland D, Larsen JP. Progression of motor impairment and disability in Parkinson disease: a population-based study. Neurology 2005;65:1436-1441.
34. Levy G, Louis ED, Cote L, et al. Contribution of aging to the severity of different motor signs in Parkinson disease. Arch Neurol 2005;62:467-472.
35. Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology 2001;57: 1497-1499.
36. O'Neill J, Schuff N, Marks WJ Jr, Feiwell R, Aminoff MJ, Weiner MW. Quantitative 1H magnetic resonance spectroscopy and MRI of Parkinson's disease. Mov Disord 2002;17:917-927.